We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care

By LabMedica International staff writers
Posted on 08 Mar 2024
Print article
Image: The Selux PBC Separator with Selux AST System has received FDA 510(k) clearance (Photo courtesy of Selux Diagnostics)
Image: The Selux PBC Separator with Selux AST System has received FDA 510(k) clearance (Photo courtesy of Selux Diagnostics)

Bacteria are outpacing scientific advancements, leading to a worrying increase in antibiotic resistance, a situation the World Health Organization has identified as an emerging global health crisis. The key to countering this trend lies in achieving quicker diagnostic results, comprehensive susceptibility testing across various sample types, and the ability to test against a broad range of commercially relevant antibiotics simultaneously. Now, a rapid antibiotic susceptibility testing (AST) system can provide targeted therapeutic results days faster than the current standard of care.

Selux Diagnostics (Boston, MA, USA) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Positive Blood Culture (PBC) Separator. The addition of positive blood culture sample type expands the Selux Next Generation Phenotyping (NGP) System, making this the only FDA-cleared, single-platform technology to deliver rapid AST results for both positive blood culture and isolated colonies.

The Selux PBC Separator streamlines the process for laboratories by enabling direct testing from positive blood culture samples, eliminating the need to subculture. This automated sample preparation for susceptibility testing enhances efficiency significantly. The recent FDA clearance allows the determination of bacterial susceptibility to 17 distinct antibiotic agents included in the Selux Gram Negative Panel. Previously awarded the FDA Breakthrough Designation, the Selux PBC Separator is recognized for its potential to meet the urgent need for conducting AST directly from positive blood culture samples and other sterile body fluids.

"This third 510(k) clearance for Selux marks a significant advancement in infectious disease care,” said Steve Lufkin, CEO of Selux Diagnostics. “The Selux NGP System is the only AST platform able to deliver rapid AST results direct from positive blood culture and isolated colonies. We extend our gratitude to our employees, partners, and advisors whose contributions were instrumental in achieving this breakthrough designated accomplishment."

Related Links:
Selux Diagnostics

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Dengue Virus Test

Print article


Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more

Molecular Diagnostics

view channel
Image: Schematic illustration of the SEDphone system workflow (Photo courtesy of ZHU Cancan)

Smartphone-Controlled Microfluidic Device Enables Rapid Influenza Detection

The influenza virus represents a significant public health concern, annually causing epidemics with high morbidity and mortality rates. The virus is known for its high mutation rate and the existence of... Read more


view channel
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)

New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched... Read more


view channel
Image: High-speed brightfield scanners offer excellent image quality to aid pathologists\' review of digital slides (Photo courtesy of Roche)

Whole-Slide Imaging System Enables Pathologists to Diagnose Patients Using Digital Images

Digital pathology involves the digitalization of the traditional pathology workflow, starting from slide scanning to visualization, to analysis. Digital pathology is transforming traditional histopathology... Read more


view channel
Image: The global urinalysis market is projected to grow at a CAGR of 9.6% to USD 6.8 billion by 2029 (Photo courtesy of Shutterstock)

Global Urinalysis Market Driven by Technological Advancements in POC Testing

Urinalysis is a practical and efficient technique for analyzing urine samples to detect various infections and chronic diseases such as diabetes, urinary tract infections, and kidney disease.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.